PHARMACOKINETICS, SAFETY AND TOLERABILITY OF THE HCV NS5A INHIBITOR ABT-267 FOLLOWING SINGLE AND MULTIPLE DOSES IN HEALTHY ADULT VOLUNTEERS

被引：14
|
作者：
Dumas, E. O. [1 ]
Lawal, A. [1 ]
Menon, R. M. [1 ]
Podsadecki, T. [1 ]
Awni, W. [1 ]
Dutta, S. [1 ]
Williams, L. [1 ]
机构：
[1] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
JOURNAL OF HEPATOLOGY | 2011年 / 54卷
关键词：
D O I：
10.1016/S0168-8278(11)61206-3
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1204
引用
收藏
页码：S475 / S476
页数：2
相关论文
共 50 条
  • [41] PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF PSI-352938, A NOVEL NUCLEOTIDE POLYMERASE INHIBITOR FOR HCV, FOLLOWING SINGLE ASCENDING ORAL DOSES IN HEALTHY SUBJECTS
    Symonds, William
    Denning, Jill M.
    Albanis, Efsevia
    Wright, Robert
    Lai, Alexander
    Berrey, Michelle
    HEPATOLOGY, 2010, 52 (04) : 1219A - 1219A
  • [42] Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Benfotiamine in Healthy Subjects
    Sheng, Lei
    Cao, Wei
    Lin, Pingping
    Chen, Weili
    Xu, Hongrong
    Zhong, Chunjiu
    Yuan, Fei
    Chen, Hanjing
    Li, Hui
    Liu, Chao
    Yang, Mengjie
    Li, Xuening
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 1101 - 1110
  • [43] Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic Hepatitis C Virus NS5A Inhibitor, in Healthy Subjects
    Mogalian, Erik
    German, Polina
    Kearney, Brian P.
    Yang, Cheng Yong
    Brainard, Diana
    Link, John
    McNally, John
    Han, LingLing
    Ling, John
    Mathias, Anita
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (05)
  • [44] Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects
    Iwamoto, M.
    Wenning, L. A.
    Petry, A. S.
    Laethem, M.
    De Smet, M.
    Kost, J. T.
    Merschman, S. A.
    Strohmaier, K. M.
    Ramael, S.
    Lasseter, K. C.
    Stone, J. A.
    Gottesdiener, K. M.
    Wagner, J. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (02) : 293 - 299
  • [45] Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GSK2336805, an Inhibitor of Hepatitis C Virus (HCV) NS5A, in Healthy Subjects and Subjects Chronically Infected with HCV Genotype 1
    Wilfret, D. A.
    Walker, J.
    Adkison, K. K.
    Jones, L. A.
    Lou, Y.
    Gan, J.
    Castellino, S.
    Moseley, C. L.
    Horton, J.
    de Serres, M.
    Culp, A.
    Goljer, I.
    Spreen, W.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (10) : 5037 - 5044
  • [46] Pharmacokinetics and safety of single and multiple doses of Asacol tablets in Japanese healthy volunteers
    Hiroaki Ito
    Shigeru Furuta
    Hidetaka Sasaki
    Toyomitsu Yoshida
    Yuichi Takano
    Toshifumi Hibi
    Advances in Therapy, 2009, 26 : 749 - 761
  • [47] Pharmacokinetics and safety of single and multiple doses of Asacol tablets in Japanese healthy volunteers
    Ito, Hiroaki
    Furuta, Shigeru
    Sasaki, Hidetaka
    Yoshida, Toyomitsu
    Takano, Yuichi
    Hibi, Toshifumi
    ADVANCES IN THERAPY, 2009, 26 (08) : 749 - 761
  • [48] Lack of Pharmacokinetic Interaction Between HCV Protease Inhibitor MK-5172 and HCV NS5A Inhibitor Daclatasvir in Healthy Volunteers
    Yeh, Wendy W.
    Fraser, Iain P.
    Bifano, Marc
    Caro, Luzelena
    Talaty, Jennifer E.
    Guo, Zifang
    McCarthy, Jennifer M.
    Youngberg, Stephen P.
    Butterton, Joan R.
    HEPATOLOGY, 2013, 58 : 430A - 431A
  • [49] Safety, tolerability, pharmacodynamics and pharmacokinetics of teverelix following single or repeated doses administered subcutaneously to healthy female volunteers.
    Maclean, CM
    Larsen, F
    Beglinger, C
    Piechatzek, R
    Drewe, J
    FERTILITY AND STERILITY, 2005, 84 : S352 - S353
  • [50] The effect of renal impairment on single-dose pharmacokinetics of daclatasvir, an HCV NS5A inhibitor
    Garimella, T.
    Wang, R.
    Luo, W.
    Hwang, C.
    Sherman, D.
    Kandoussi, H.
    Marbury, T.
    Alcorn, H.
    Bertz, R.
    Bifano, M.
    JOURNAL OF VIRAL HEPATITIS, 2014, 21 : 32 - 32
12345